Karsten Imke E, Reinartz Gabriele, Pixberg Michaela, Kröger Kai, Oertel Michael, Friedrichs Birte, Lenz Georg, Eich Hans Theodor
Department of Radiation Oncology, University Hospital of Muenster, 48149 Muenster, Germany.
Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, 48149 Muenster, Germany.
Biomedicines. 2021 May 17;9(5):561. doi: 10.3390/biomedicines9050561.
This retrospective study examined the role of F-fluorodeoxyglucose-positron emission tomography/computed tomography (F-FDG-PET/CT) in stage-related therapy of follicular lymphomas (FL). Twelve patients each in stages I and II, 13 in stage III and 11 in stage IV were treated in the Department of Radiation Oncology, University Hospital of Muenster, Germany from 2004 to 2016. Radiotherapy (RT), as well as additional chemoimmunotherapy were analyzed with a median follow-up of 87.6 months. Ultrasound (US), CT and F-FDG-PET/CT were used to determine progression-free survival (PFS), overall survival (OS) and lymphoma-specific survival (LSS) over 5- and 10- years. 23 of 24 patients with stage I/II (95.8%) had complete remissions (CR) and 17 of 24 patients with stages III/IV FL showed CR (70.8%). 5- and 10-year PFS in stages I/II was 90.0%/78.1% vs. 44.3%/28.5% in stages III/IV. 5- and 10-year OS rates in stages I/II was 100%/93.3% vs. 53.7%/48.4% in stages III/IV. 5- and 10-year LSS of stages I/II was 100%/93.8% vs. 69.2%/62.3% in stages III/IV. FL of stages I/II, staged by F-FDG-PET/CT, revealed better survival rates and lower risk of recurrence compared to studies without PET/CT-staging. Especially, patients with PET/CT proven stage I disease showed significantly better survival and lower relapses rates after RT.
这项回顾性研究探讨了氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（F-FDG-PET/CT）在滤泡性淋巴瘤（FL）分期相关治疗中的作用。2004年至2016年期间，德国明斯特大学医院放射肿瘤学系对12例I期和II期、13例III期和11例IV期的患者进行了治疗。对放疗（RT）以及额外的化疗免疫治疗进行了分析，中位随访时间为87.6个月。使用超声（US）、CT和F-FDG-PET/CT来确定5年和10年的无进展生存期（PFS）、总生存期（OS）和淋巴瘤特异性生存期（LSS）。24例I/II期患者中有23例（95.8%）完全缓解（CR），24例III/IV期FL患者中有17例（70.8%）显示CR。I/II期的5年和10年PFS分别为90.0%/78.1%，而III/IV期为44.3%/28.5%。I/II期的5年和10年OS率分别为100%/93.3%，而III/IV期为53.7%/48.4%。I/II期的5年和10年LSS分别为100%/93.8%，而III/IV期为69.2%/62.3%。与未进行PET/CT分期的研究相比，通过F-FDG-PET/CT分期的I/II期FL显示出更好的生存率和更低的复发风险。特别是，PET/CT证实为I期疾病的患者在放疗后显示出明显更好的生存率和更低的复发率。
